Journal of Clinical Oncology
Articles in this Issue
Comparison of real-world effectiveness of all approved BRAF/MEK inhibitor combinations in <i>BRAF</i> -mutant melanoma patients.
e21525 Background: Currently, three distinct combinations of BRAF and MEK inhibitors (BRAFi/MEKi) are approved for treatme...
A capacity assessment of pediatric oncology research biorepositories across a regional collaborative group in the Middle East, North Africa, and Asia.
10023 Background: Biobanks advance translational research in pediatric oncology. Understanding the existing biobanking inf...
Trastuzumab (Tmab) plus chemotherapy (CT) vs CT alone in the perioperative treatment of HER2-positive gastric cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
e16129 Background: HER2 overexpression occurs in 15-20% of gastric cancers (GC) and is associated with poor prognosis. Whi...
Artificial intelligence and machine learning for predicting immune checkpoint inhibitor–associated cardiotoxicity: A systematic review and narrative synthesis.
e24028 Background: Immune checkpoint inhibitor (ICI) associated cardiotoxicity, including myocarditis and major adverse ca...
Trial-level association between age-enriched populations and treatment effect in frontline randomized multiple myeloma studies.
e19555 Background: Age at diagnosis has traditionally been considered a host-related factor in MM, influencing treatment t...
Neoadjuvant anti–PD-1 prolgolimab monotherapy in resectable high-risk melanoma: Pathologic response and early event-free survival in a prospective single-arm phase II CRISTINA study.
9579 Background: In resectable high-risk melanoma, neoadjuvant anti–PD-1 aims to exceed the ~40% MPR benchmark; while comb...
Burden and site-specific spectrum of second primary malignancies after adult acute myeloid leukemia: A population-based SEER standardized incidence ratio study with latency-stratified risk profiling (2000–2022).
11070 Background: As survival after acute myeloid leukemia (AML) improves, second primary malignancies (SPMs) represent an...
Multi-modal liquid biopsy integrating cfDNA fragmentomics and serum biomarkers for the differential diagnosis of ovarian tumors.
5573 Background: Ovarian cancer (OC) remains the leading cause of mortality among gynecological malignancies, primarily du...
Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of <sup>177</sup> Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).
5019 Background: The PLUDO trial randomized patients with mCRPC to receive either LuP or DOC, with cross-over permitted at...
XNW27011, a Claudin 18.2(CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A phase 2 study.
3036 Background: The prognosis of G/GEJA remains poor, especially in late line patients (pts). mPFS for G/GEJA pts who rec...
CCTG BR.38: Consolidative use of radiotherapy to block (CURB2) oligoprogression in patients with metastatic non–small-cell lung cancer—A randomized phase III trial.
TPS8124 Background: Immune checkpoint inhibitor (ICI)–based regimens are standard first-line therapy for metastatic non–sm...
Cancer survival for rural and urban populations during the opioid epidemic: A SEER analysis.
e23065 Background: The opioid epidemic has disproportionately affected rural communities, with associated increases in ove...
Prompt engineering and readability of large language model–generated patient education materials in hematology and oncology.
e13668 Background: Patients with cancer must understand complex diagnostic and treatment concepts to make informed healthc...
Cross-platform concordance between tumor-informed and tumor-naive ctDNA MRD assays in early-stage NSCLC: A paired-sample pilot comparison of Signatera and Guardant Reveal.
e20082 Background: Circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) assays are increasingly integrated i...
A single-institution retrospective analysis of the distinct differences between spontaneous malignant transformation and treatment-associated transformation in <i>IDH</i> -mutant gliomas.
e14094 Background: Malignant transformation (MT) of IDH mutant gliomas is a poorly...
Real-world patterns of aspirin and anticoagulant prophylaxis at IMiD-associated VTE onset in multiple myeloma: A phase-specific analysis.
e19534 Background: Immunomodulatory drugs (IMiDs) increase venous thromboembolism (VTE) risk in multiple myeloma (MM). Gui...
AKY-2519, a novel B7-H3-targeted radioconjugate, and its biodistribution profile in patients with mCRPC.
3097 Background: AKY-2519 is a 6.1 kDa B7-H3 (CD276) targeting miniprotein with an N-terminal short polyethylene glycol li...
Analysis of corticosteroid exposure on efficacy of tarlatamab in small cell lung cancer: A multicenter retrospective study.
8088 Background: Tarlatamab, a delta-like ligand 3 (DLL3)-targeted bispecific T-cell engager, has shown meaningful activit...
Association of high-grade biology with marked salvage refractoriness following CD19 CAR T-cell therapy failure in large B-cell lymphoma: A systematic review and meta-analysis.
e19013 Background: CD19 chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for relapsed or refractory la...
A molecular subtype–guided, chemotherapy-free neoadjuvant strategy using SHR-A1811 plus pertuzumab for hormone receptor–positive/HER2-positive breast cancer: A phase II trial in progress.
TPS653 Background: Hormone receptor–negative/HER2-positive breast cancer achieves high pathological complete response (pCR...
Osimertinib plus savolitinib in osimertinib-resistant non-small-cell lung cancer with low level gene copy number MET: A multi-center, open-label, and phase 2 study.
e20079 Background: MET-based resistance following osimertinib treatment for epidermal growth factor receptor (EGFR)-mutate...
Early-onset gastrointestinal cancers: Rural-urban divide and cancer-site disparities in outcomes.
e23203 Background: Early-onset gastrointestinal (eoGI) cancers, defined as diagnoses occurring before age 50, represent a...
Depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab.
6040 Background: In HPV-negative HNSCC, TGF-β overexpression creates fibrotic barriers within the tumor microenvironment t...
Early detection of kidney cancer using blood-based multi-gene mRNA profiling in a prospective clinical study.
4542 Background: Kidney cancer remains one of the most aggressive and lethal urological malignancies, largely due to late-...
A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed <i>NPM1</i> -mutated acute myeloid leukemia (REVEAL-ND NPM1).
TPS6602 Background: There are currently no approved targeted therapies for newly diagnosed (ND) acute myeloid leukemia (AM...